�Researchers with Vanderbilt-Ingram Cancer Center take discovered one of the clues that may excuse how a common stomach bacteria privy trigger stomach cancer.
Helicobacter pylori infects nearly 50 percent of the population and is the strongest known risk factor for gastric malignant neoplastic disease. However, entirely a fraction of those infected with H. pylori develop cancer, so researchers have been trying to define the pathways that lead to cancer development.
Richard Peek Jr., M.D., director of the Division of Gastroenterology, Hepatology and Nutrition at Vanderbilt-Ingram Cancer Center, and colleagues at the Nashville Veterans Affairs Medical Center investigated a cag+ strain of H. pylori - a strain that increases risk of peptic ulcers and stomachic cancer - in mouse models. They determined that an H. pylori protein switches on a prison cell receptor called Decay-accelerating divisor (DAF) and that DAF protects septic gastric cells from the immune scheme. Their findings were published in the Aug. 29 issue of the Journal of Biological Chemistry.
"We found that the bacteria had actually co-opted a host cell protein, utilizing it as a receptor," said Peek. "This facilitated infection of the stomach and initiation of stomachal inflammation and injury."
Peek and his colleagues likewise found that up-regulation of DAF saying by H. pylori lED to dogged inflammation in the stomach, making it easier for diseases like cancer to develop.
Daniel P. O'Brien, Ph.D. was lead author on the paper. Other researchers include Judith Romero-Gallo, B.A., Barbara G. Schneider, Ph.D., Rupesh Chaturvedi, Ph.D., Alberto Delgado, B.A., Elizabeth J. Harris, M.D., Uma Krishna, B.A., Seth R. Ogden, B.A., Dawn A. Israel, Ph.D. and Keith T. Wilson, M.D.
The research was supported by the National Institutes of Health, the Vanderbilt Digestive Diseases Research Center and the Office of Medical Research, Department of Veterans Affairs.
The Vanderbilt-Ingram Cancer Center is a National Cancer Institute Comprehensive Cancer Center, one of two centers in Tennessee and 41 in the country to earn this highest differentiation. Its intimately 300 staff members generate more than $140 1000000 in annual federal research funding, ranking it among the crest 10 centers in the country in competitive grant support, and its clinical program sees approximately 4,000 raw cancer patients each year. Vanderbilt-Ingram, based in Nashville, Tenn., of late joined with 21 of the world's leading centers in the National Comprehensive Cancer Network, a nonprofit alliance consecrate to up cancer upkeep for patients everywhere.
Vanderbilt-Ingram Cancer Center
More info
